Eli Lilly's lymphoma drug fails in late-stage trial
May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival.
The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following a chemotherapy treatment. Lymphoma is a cancer of the lymphatic system.
The decision to stop the drug's development will result in a second-quarter charge of about $30 million but the company's 2013 forecast remained unchanged, Lilly said in a statement.
- Police hunt for motive as search for Malaysian jet spans hemispheres |
- Russia media say Crimea votes 93 percent to quit Ukraine |
- Ukraine, Russia agree Crimea truce until March 21-Ukraine minister
- Malaysian PM says lost airliner was diverted deliberately |
- Democrats seek ways to limit Obamacare fallout after Florida defeat